Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Randomized CARES trial of anti-fibril antibody anselamimab in AL amyloidosis did not meet primary end point in overall population but improved all-cause mortality cardiovascular hospitalizations in patients with kappa AL.”
Title: Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials
Authors: Ashutosh D. Wechalekar, Angela Dispenzieri, Vaishali Sanchorawala, Efstathios Kastritis, Divaya Bhutani, Giada Bianchi, Victor H. Jimenez-Zepeda, Kenshi Suzuki, Suzanne Lentzsch, Antoine Huart, Alexander Carpinteiro, Eugene Scott Swenson, Zilehuma Khan, Julia Catini, Hrishikesh Kulkarni, Brian Meltzer, Stephen Lake, Michaela Liedtke
You can read the Full Article on Journal of Clinical Oncology.
You can find other articles featuring Robert Orlowski on OncoDaily.
